| 2029년 6월 23일 2020년 6월 25일 제출 | Brophy Michael Burkes Officer: Chief Financial Officer | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 처분(D) | 12,500 | 0 | — | 37,500 | 직접(D) | 이 양식 버전에는 없음 | F2, F7 - F2 Each RSU represents a contingent right to receive one share of the common stock of the issuer.
- F7 On March 22, 2019, the Reporting Person was granted RSUs covering 100,000 shares of common stock, which vests in tranches upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. On June 23, 2020, the criteria was satisfied for the vesting of RSUs covering 12,500 shares of common stock.
| 제출 문서 열기 0001179110-20-007780 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2029년 6월 8일 2020년 6월 10일 제출 | Brophy Michael Burkes Officer: Chief Financial Officer | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 처분(D) | 25,000 | 0 | — | 50,000 | 직접(D) | 이 양식 버전에는 없음 | F2, F6 - F2 Each RSU represents a contingent right to receive one share of the common stock of the issuer.
- F6 On March 22, 2019, the Reporting Person was granted RSUs covering 100,000 shares of common stock, which vests in tranches upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. On June 8, 2020, the criteria was satisfied for the vesting of RSUs covering 25,000 shares of common stock.
| 제출 문서 열기 0001179110-20-007206 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 40 | 315.26 | 12,610.4 산출: 주식 수 × 주당 가격. 정확한 값 12610.40. | 8,210 | 간접(I) by Caraluna 1 Trust | 예 | F1, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 85 | 316.9256 | 26,938.676 산출: 주식 수 × 주당 가격. 정확한 값 26938.6760. | 8,125 | 간접(I) By Caraluna 1 Trust | 예 | F1, F3, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.4100 to $317.4050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 145 | 317.8748 | 46,091.846 산출: 주식 수 × 주당 가격. 정확한 값 46091.8460. | 7,980 | 간접(I) By Caraluna 1 Trust | 예 | F1, F4, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.56 to $318.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 240 | 319.7733 | 76,745.592 산출: 주식 수 × 주당 가격. 정확한 값 76745.5920. | 7,740 | 간접(I) By Caraluna 1 Trust | 예 | F1, F5, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.8350 to $319.5250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 160 | 320.0188 | 51,203.008 산출: 주식 수 × 주당 가격. 정확한 값 51203.0080. | 7,580 | 간접(I) By Caraluna 1 Trust | 예 | F1, F6, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.87 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 40 | 322 | 12,880 산출: 주식 수 × 주당 가격. 정확한 값 12880. | 7,540 | 간접(I) By Caraluna 1 Trust | 예 | F1, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 40 | 323.0650 | 12,922.6 산출: 주식 수 × 주당 가격. 정확한 값 12922.6000. | 7,500 | 간접(I) By Caraluna 1 Trust | 예 | F1, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 40 | 315.28 | 12,611.2 산출: 주식 수 × 주당 가격. 정확한 값 12611.20. | 8,210 | 간접(I) By Caraluna 2 Trust | 예 | F1, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 48 | 317.3253 | 15,231.6144 산출: 주식 수 × 주당 가격. 정확한 값 15231.6144. | 8,162 | 간접(I) By Caraluna 2 Trust | 예 | F1, F7, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.5200 to $317.4050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 182 | 317.9626 | 57,869.1932 산출: 주식 수 × 주당 가격. 정확한 값 57869.1932. | 7,980 | 간접(I) By Caraluna 2 Trust | 예 | F1, F8, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F8 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.56 to $318.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 240 | 319.2167 | 76,612.008 산출: 주식 수 × 주당 가격. 정확한 값 76612.0080. | 7,740 | 간접(I) By Caraluna 2 Trust | 예 | F1, F9, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F9 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.8350 to $319.5500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 120 | 320.0683 | 38,408.196 산출: 주식 수 × 주당 가격. 정확한 값 38408.1960. | 7,620 | 간접(I) By Caraluna 2 Trust | 예 | F1, F10, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F10 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.9450 to $320.2600 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 80 | 322.8750 | 25,830 산출: 주식 수 × 주당 가격. 정확한 값 25830.0000. | 7,540 | 간접(I) By Caraluna 2 Trust | 예 | F1, F11, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F11 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.62 to $323.13 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 11일 2026년 11월 13일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 40 | 324.76 | 12,990.4 산출: 주식 수 × 주당 가격. 정확한 값 12990.40. | 7,500 | 간접(I) By Caraluna 2 Trust | 예 | F1, F2 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
| 제출 문서 열기 0001646649-26-000045 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 15 | 304.5713 | 4,568.5695 산출: 주식 수 × 주당 가격. 정확한 값 4568.5695. | 217,597 | 직접(D) | 예 | F1, F2, F3 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.24 to $304.95 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3 Includes 38 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on October 31, 2026
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 51 | 305.7527 | 15,593.3877 산출: 주식 수 × 주당 가격. 정확한 값 15593.3877. | 217,546 | 직접(D) | 예 | F1, F4 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.30 to $306.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 21 | 306.4633 | 6,435.7293 산출: 주식 수 × 주당 가격. 정확한 값 6435.7293. | 217,525 | 직접(D) | 예 | F1, F5 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.39 to $306.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 50 | 308.1980 | 15,409.9 산출: 주식 수 × 주당 가격. 정확한 값 15409.9000. | 217,475 | 직접(D) | 예 | F1, F6 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.70 to $308.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 64 | 309.0817 | 19,781.2288 산출: 주식 수 × 주당 가격. 정확한 값 19781.2288. | 217,411 | 직접(D) | 예 | F1, F7 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $308.7200 to $309.6450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 110 | 310.1655 | 34,118.205 산출: 주식 수 × 주당 가격. 정확한 값 34118.2050. | 217,301 | 직접(D) | 예 | F1, F8 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F8 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.81 to $310.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 100 | 311.3116 | 31,131.16 산출: 주식 수 × 주당 가격. 정확한 값 31131.1600. | 217,201 | 직접(D) | 예 | F1, F9 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F9 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.99 to $311.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 106 | 312.1965 | 33,092.829 산출: 주식 수 × 주당 가격. 정확한 값 33092.8290. | 217,095 | 직접(D) | 예 | F1, F10 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F10 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.00 to $312.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 74 | 313.3168 | 23,185.4432 산출: 주식 수 × 주당 가격. 정확한 값 23185.4432. | 217,021 | 직접(D) | 예 | F1, F11 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F11 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.01 to $314.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 108 | 314.7084 | 33,988.5072 산출: 주식 수 × 주당 가격. 정확한 값 33988.5072. | 216,913 | 직접(D) | 예 | F1, F12 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F12 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.04 to $315.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 169 | 315.4827 | 53,316.5763 산출: 주식 수 × 주당 가격. 정확한 값 53316.5763. | 216,744 | 직접(D) | 예 | F1, F13 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F13 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.0900 to $316.0750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 1,838 | 316.8674 | 582,402.2812 산출: 주식 수 × 주당 가격. 정확한 값 582402.2812. | 214,906 | 직접(D) | 예 | F1, F14 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F14 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.24 to $317.14 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 56 | 318.1661 | 17,817.3016 산출: 주식 수 × 주당 가격. 정확한 값 17817.3016. | 214,850 | 직접(D) | 예 | F1, F15 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F15 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.36 to $318.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 105 | 319.2993 | 33,526.4265 산출: 주식 수 × 주당 가격. 정확한 값 33526.4265. | 214,745 | 직접(D) | 예 | F1, F16 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F16 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.67 to $319.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 131 | 320.0673 | 41,928.8163 산출: 주식 수 × 주당 가격. 정확한 값 41928.8163. | 214,614 | 직접(D) | 예 | F1, F17 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F17 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.67 to $320.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 51 | 321.1191 | 16,377.0741 산출: 주식 수 × 주당 가격. 정확한 값 16377.0741. | 214,563 | 직접(D) | 예 | F1, F18 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F18 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.77 to $321.63 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 16 | 321.85 | 5,149.6 산출: 주식 수 × 주당 가격. 정확한 값 5149.60. | 214,547 | 직접(D) | 예 | F1 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 40 | 323.8590 | 12,954.36 산출: 주식 수 × 주당 가격. 정확한 값 12954.3600. | 214,507 | 직접(D) | 예 | F1, F19 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F19 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.3800 to $324.3550 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 6일 2026년 11월 10일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 45 | 325.0509 | 14,627.2905 산출: 주식 수 × 주당 가격. 정확한 값 14627.2905. | 214,462 | 직접(D) | 예 | F1, F20 - F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F20 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.56 to $325.53 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0001646649-26-000044 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 3일 2026년 11월 4일 제출 | Brophy Michael Burkes Officer: CHIEF FINANCIAL OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 470 | 391.49 | 184,000.3 산출: 주식 수 × 주당 가격. 정확한 값 184000.30. | 45,779 | 직접(D) | 예 | F2 - F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025.
| 제출 문서 열기 0001697362-26-000024 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Fesko John Officer: PRESIDENT, CHIEF BUS. OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 7 | 388.2001 | 2,717.4007 산출: 주식 수 × 주당 가격. 정확한 값 2717.4007. | 195,571 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0002010135-26-000028 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Fesko John Officer: PRESIDENT, CHIEF BUS. OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 295 | 400.2942 | 118,086.789 산출: 주식 수 × 주당 가격. 정확한 값 118086.7890. | 195,276 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0002010135-26-000028 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Rabinowitz Matthew Director · Officer: EXECUTIVE CHAIRMAN | S Open market or private sale of non-derivative or derivative security | 처분(D) | 17 | 388.20 | 6,599.4 산출: 주식 수 × 주당 가격. 정확한 값 6599.40. | 2,117,659 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001646382-26-000029 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Rabinowitz Matthew Director · Officer: EXECUTIVE CHAIRMAN | S Open market or private sale of non-derivative or derivative security | 처분(D) | 731 | 400.2942 | 292,615.0602 산출: 주식 수 × 주당 가격. 정확한 값 292615.0602. | 2,116,928 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001646382-26-000029 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 3 | 388.20 | 1,164.6 산출: 주식 수 × 주당 가격. 정확한 값 1164.60. | 217,683 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001646649-26-000043 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Sheena Jonathan Director · Other: CO-FOUNDER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 109 | 400.2942 | 43,632.0678 산출: 주식 수 × 주당 가격. 정확한 값 43632.0678. | 217,574 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001646649-26-000043 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Brophy Michael Burkes Officer: CHIEF FINANCIAL OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 8 | 388.0301 | 3,104.2408 산출: 주식 수 × 주당 가격. 정확한 값 3104.2408. | 46,566 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001697362-26-000024 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Brophy Michael Burkes Officer: CHIEF FINANCIAL OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 317 | 400.2942 | 126,893.2614 산출: 주식 수 × 주당 가격. 정확한 값 126893.2614. | 46,249 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001697362-26-000024 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | RABINOWITZ DANIEL Officer: SEC. AND CHIEF LEGAL OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 7 | 388.20 | 2,717.4 산출: 주식 수 × 주당 가격. 정확한 값 2717.40. | 168,214 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001857843-26-000033 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | RABINOWITZ DANIEL Officer: SEC. AND CHIEF LEGAL OFFICER | S Open market or private sale of non-derivative or derivative security | 처분(D) | 334 | 400.2942 | 133,698.2628 산출: 주식 수 × 주당 가격. 정확한 값 133698.2628. | 167,880 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0001857843-26-000033 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS | S Open market or private sale of non-derivative or derivative security | 처분(D) | 9 | 388.2001 | 3,493.8009 산출: 주식 수 × 주당 가격. 정확한 값 3493.8009. | 104,733 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0002010019-26-000038 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS | S Open market or private sale of non-derivative or derivative security | 처분(D) | 410 | 400.2942 | 164,120.622 산출: 주식 수 × 주당 가격. 정확한 값 164120.6220. | 104,323 | 직접(D) | 예 | F1 - F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
| 제출 문서 열기 0002010019-26-000038 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS | S Open market or private sale of non-derivative or derivative security | 처분(D) | 200 | 405.2560 | 81,051.2 산출: 주식 수 × 주당 가격. 정확한 값 81051.2000. | 104,123 | 직접(D) | 예 | F2, F3 - F2 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
- F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $404.8500 to $405.8450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0002010019-26-000038 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2026년 11월 2일 2026년 11월 4일 제출 | Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS | S Open market or private sale of non-derivative or derivative security | 처분(D) | 432 | 406.9398 | 175,797.9936 산출: 주식 수 × 주당 가격. 정확한 값 175797.9936. | 103,691 | 직접(D) | 예 | F2, F4 - F2 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
- F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $406.4150 to $407.3750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
| 제출 문서 열기 0002010019-26-000038 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
Fundies.